Patents Examined by Jared Barsky
  • 4-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives for use as BCRP inhibitors in therapeutic treatments
    Patent number: 10975079
    Abstract: The present invention relates to 5-amino-3-phenylamino-6-phenylpyrazolo[3,4-d]pyrimidine derivatives of the general formula (I) or pharmaceutically acceptable salts or propharmacons thereof for use as BCRP inhibitors, wherein at least one hydrogen atom in at least one of the phenyl groups A and B is substituted by a substituent RH, which has a Hammett constant ?p greater than 0.23. For corresponding compounds, surprisingly a particularly high inhibitory activity against BCRP has been discovered which can be exploited for suppressing the multidrug resistance modulator BCRP, thus providing an improvement in efficacy of BCRP affected drugs. This has useful implications for cancer and HIV treatment.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: April 13, 2021
    Assignee: Scandion Oncology A/S
    Inventors: Steffen Rump, Henning Weigt
  • Treatment of relapsed and/or refractory solid tumors and non-hodgkin's lymphomas
    Patent number: 10960005
    Abstract: Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).
    Type: Grant
    Filed: June 10, 2020
    Date of Patent: March 30, 2021
    Assignee: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: Jiangchun Xu, Robert Cho, Aaron Nguyen
  • Pyridine-2-carboxamides as nematocides
    Patent number: 10952435
    Abstract: Compounds of the formula (I), in which the substituents are as defined in claim 1, are suitable for use as nematicides.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: March 23, 2021
    Assignee: SYNGENTA PARTICIPATIONS AG
    Inventors: Olivier Loiseleur, Andre Jeanguenat, Regis Jean Georges Mondiere
  • Metabolism-improving agent comprising rare fatty acid
    Patent number: 10952983
    Abstract: The invention provides a metabolism improving agent containing a rare fatty acid such as hydroxylated fatty acid, oxo fatty acid and the like, and further, food, pharmaceutical product and the like containing the metabolism improving agent.
    Type: Grant
    Filed: December 11, 2019
    Date of Patent: March 23, 2021
    Assignees: KYOTO UNIVERSITY, NITTO PHARMACEUTICAL INDUSTRIES, LTD.
    Inventors: Jun Ogawa, Shigenobu Kishino, Teruo Kawada, Nobuyuki Takahashi, Tsuyoshi Goto, Yasunori Yonejima
  • Imipridones for gliomas
    Patent number: 10946022
    Abstract: Imipridones selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and are useful for treating conditions and disorders in need of such modulation, such as cancers. Specifically, the cancer is a midline glioma, a cancer having a histone H3 mutation, or both. In addition, methods of identifying whether a subject having these conditions, is likely to be responsive to a treatment regimen, such as imipridone administration, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as imipridone administration, monitoring, or providing a prognosis for a subject with these condition are also provided.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: March 16, 2021
    Assignee: ONCOCEUTICS, INC.
    Inventors: Joshua E. Allen, Martin Stogniew, Varun Vijay Prabhu
  • Kinase inhibitor salts and compositions thereof
    Patent number: 10940149
    Abstract: The present invention relates to polymorphic forms of nilotinib lauryl sulfate salt.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: March 9, 2021
    Assignee: HANDA ONCOLOGY, LLC
    Inventors: Fang-Yu Liu, K. C. Sung, Chin-Yao Yang, Chi-Cheng Lin, Yi-Hsin Lin, Li Qiao
  • Ophthalmic composition comprising rebamipide and method for preparing the same
    Patent number: 10918725
    Abstract: An ophthalmic composition is provided that includes rebamipide and a method for preparing the same. The ophthalmic composition of maintains its transparency for a long time even in a physiologically neutral to weakly basic pH range that does not injure the cornea and conjunctiva of a patient suffering from dry eye and has improved stability so as not to be re-dispersed.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: February 16, 2021
    Assignee: SAMJIN PHARMACEUTICAL CO., LTD.
    Inventors: Eui-Hwan Cho, Sung-Ju Choi, Sung-Woo Lee, Hee-Jong Shin, Min-Hyo Ki, Mee-Hwa Choi, Dong-Ha Lee
  • Compositions for treating CMT and related disorders
    Patent number: 10905686
    Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: February 2, 2021
    Assignee: Pharnext
    Inventors: Daniel Cohen, Serguei Nabirochkin, Ilya Chumakov
  • Oxymetazoline compositions
    Patent number: 10898573
    Abstract: The present disclosure is directed to compositions comprising oxymetazoline and methods of stabilizing oxymetazoline compositions for long term storage.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: January 26, 2021
    Assignee: RVL Pharmaceuticals, Inc.
    Inventors: Tina deVries, David Jacobs
  • Methods for solid tumor treatment
    Patent number: 10894045
    Abstract: Disclosed herein are methods for treating solid tumors by direct injection into the tumors of chemotherapeutic particles, methods for inhibiting tumor metastasis by administering chemotherapeutic particles to a subject having a tumor, and compositions that include chemotherapeutic particles, small amounts of a polysorbate, and a carrier.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: January 19, 2021
    Assignee: Crititech, Inc.
    Inventors: Mike Baltezor, Gere diZerega, Charles Decedue, Sam Campbell, Matt McClorey
  • Methods and articles of manufacture for the treatment of skin
    Patent number: 10888511
    Abstract: Embodiments of the present invention are directed to methods and articles of manufacture to treat skin to improve and/or increase hydration, pliability, and thickness for improved texture, feel and appearance. Embodiments feature applying an effective amount of an acetylation agent to natural dermal collagen under reaction conditions to react the natural dermal collagen with the acetylation agent to form a modified collagen. The modified collagen has a higher net charge and higher net charge density than natural dermal collagen. The modified collagen improves or increases one or more skin characteristics consisting of hydration, pliability and thickness.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: January 12, 2021
    Assignee: Advanced Collagen Science LLC
    Inventors: Leonard B. Miller, Dale P. Devore
  • Procaspase 3 activation by combination therapy
    Patent number: 10888560
    Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: January 12, 2021
    Assignees: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc.
    Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Howard S. Roth, Theodore M. Tarasow
  • Methods for solid tumor treatment
    Patent number: 10874660
    Abstract: Disclosed herein are methods for treating solid tumors by direct injection into the tumors of chemotherapeutic particles, methods for inhibiting tumor metastasis by administering chemotherapeutic particles to a subject having a tumor, and compositions that include chemotherapeutic particles, small amounts of a polysorbate, and a carrier.
    Type: Grant
    Filed: December 13, 2019
    Date of Patent: December 29, 2020
    Assignee: CritlTech, Inc.
    Inventors: Mike Baltezor, Gere diZerega, Charles Decedue, Sam Campbell, Matt McClorey
  • Antibacterial compounds
    Patent number: 10857110
    Abstract: An antibacterial compound of formula I, wherein X is selected from fluoro or bromo, effective against Gram negative and Gram positive bacteria, and in particular against non-fermenting multiresistant bacteria affecting patients suffering from cystic fibrosis and which are responsible of severe hospital-acquired infections in immunodepressed patients; its preparation process and pharmaceutical composition comprising said compound.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: December 8, 2020
    Assignees: CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS (CONICENT), UNIVERSIDAD NACIONAL DE LA PLATA (UNLP), QUAID-I-AZAM UNIVERSITY
    Inventors: Aamer Saeed Bhatti, María Alejandra Nieves Bosch, Yanina Andrea Lamberti, Mauricio Federico Erben
  • Methods for the administration of certain VMAT2 inhibitors
    Patent number: 10857148
    Abstract: Provided are methods of administering a vesicular monoamine transport 2 (VMAT2) inhibitor chosen from valbenazine and (+)-?-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol, or a pharmaceutically acceptable salt and/or isotopic variant thereof, to a patient in need thereof wherein the patient is also being administered digoxin.
    Type: Grant
    Filed: May 11, 2020
    Date of Patent: December 8, 2020
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: Christopher F. O'Brien, Haig P. Bozigian
  • Treatment of relapsed and/or refractory solid tumors and non-Hodgkin's lymphomas
    Patent number: 10849898
    Abstract: Methods are provided for the treatment of relapsed and/or refractory solid tumors (including neuroendocrine carcinomas (NEC)) and non-Hodgkin's lymphomas (NHLs) and the like, using substituted heterocyclic derivative compounds and pharmaceutical compositions comprising compounds useful for the inhibition of lysine specific demethylase-1 (LSD-1).
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: December 1, 2020
    Assignee: CELGENE QUANTICEL RESEARCH, INC.
    Inventors: Jiangchun Xu, Robert Cho, Aaron Nguyen
  • Nasal spray using C60 and curcumin
    Patent number: 10842738
    Abstract: A nutraceutical composition comprising fullerene (e.g., C60), curcumin, and a medium chain triglyceride. Preferably, blackseed oil is used to provide medium chain triglyceride. The nutraceutical composition can be packaged in a mist-producing device and used as a nasal spray or an inhaler. Preferably, the nasal spray is substantially free of particles having a size greater than 0.2 ?m. The nutraceutical composition can be used to treat respiratory conditions (e.g., asthma, nasal polyps, etc.) or brain disorders through nasal spray, inhaling, or oral administration.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: November 24, 2020
    Inventor: Max C. Champie
  • Muscarinic agonists as cognitive enhancers
    Patent number: 10835532
    Abstract: Methods of treating a mental condition by administering to a subject in need thereof an effective amount of compound CDD-102A, [5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine] are described.
    Type: Grant
    Filed: October 17, 2013
    Date of Patent: November 17, 2020
    Assignees: The University of Toledo, The Board of Trustees of the University of Illinois
    Inventors: William S. Messer, Jr., Michael E. Ragozzino
  • Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency
    Patent number: 10828267
    Abstract: Disclosed herein are therapeutic regimens for improving visual function in Retinitis Pigmentosa and other visual disorders associated with an endogenous retinoid deficiency in a subject by administering a therapeutically effective amount of a synthetic retinal derivative, for example a 9- or 11-cis retinyl ester, according to the therapeutic regimen which leads to local recovery of visual functions such as visual fields, visual acuity and retinal sensitivity, among others.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: November 10, 2020
    Assignee: RETINAGENIX THERAPEUTICS, INC.
    Inventor: Suzanne Cadden
  • Pharmaceutical composition for preventing or treating AIDS comprising rhodanine derivative
    Patent number: 10821101
    Abstract: The present invention relates to a pharmaceutical composition for preventing or treating AIDS, comprising a rhodanine derivative and a nucleoside reverse transcriptase inhibitor. A complex composition of the present invention exhibits a synergistic effect in terms of anti-HIV activity as compared with a case where each of the compounds is used as a single drug. Thus, the composition provides sufficient anti-HIV activity and exhibits an excellent effect of decreasing side effects such as toxicity even in a case where each compound is administered in a small amount. Accordingly, the present invention is expected to greatly contribute to treatment of AIDS patients.
    Type: Grant
    Filed: August 29, 2019
    Date of Patent: November 3, 2020
    Assignee: AVIXGEN INC.
    Inventors: Min Jung Kim, Jun Sub Choi, Hye Cheong Koo, Yi Yong Baek